Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 13/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 0.90 |
| ▸ | RAB9A | P51151 | 5/20 | 0.90 |
| ▸ | LMNA | P02545 | 4/20 | 0.90 |
| ▸ | HTT | P42858 | 2/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839937 | 0.95 | WDR5 (0.90) | WDR5ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL9700032 | 0.84 | WDR5 (0.73) | WDR5ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL4839735 | 0.83 | WDR5 (0.71) | WDR5ALDH1A1NPC1RAB9ALMNA | |
| Bromide SCHEMBL9839171 | 0.83 | WDR5 (0.71) | WDR5ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL7380842 | 0.80 | WDR5 (0.65) | WDR5ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL9293256 | 0.79 | WDR5 (0.66) | WDR5ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL18329398 | 0.79 | WDR5 (0.65) | WDR5ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL9199162 | 0.79 | WDR5 (1.00) | WDR5ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL9698908 | 0.78 | LMNA (0.70) | WDR5ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL5308466 | 0.78 | ALDH1A1 (0.70) | WDR5ALDH1A1NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-9290517-B2 | Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150284411-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-10-08 | — | — | US | disclosed |
| EP-2888005-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| CN-104718004-A | Novel azabenzimidazole hexahydrofuro[3,2-b]furan derivatives | MERCK SHARP & DOHME | 2015-06-17 | — | — | CN | disclosed |
| WO-2014031515-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-7320995-B2 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| US-20080009506-A1 | Imidazole Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-10 | — | — | US | disclosed |
| US-20080009506-A1 | Imidazole Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1554272-B1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | LILLY CO ELI (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1654247-A1 | ALKYNYL ARYL CARBOXAMIDES | Applied Research Systems ARS Holding N.V. (AN) | 2006-05-10 | — | — | EP | disclosed |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | EIL LILLY AND COMPANY (US) | 2005-12-08 | — | — | US | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1554272-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005012280-A1 | ALKYNYL ARYL CARBOXAMIDES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004014900-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | TGFBR1, TGFBR2, SMAD3 | WDR5 3027/4885ALDH1A1 795/4885NPC1 2316/4885 |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | MAP3K8, MAPK8, MAPK1 | WDR5 1593/4885ALDH1A1 1864/4885NPC1 4504/4885 |
| US-20150284411-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES | PRKAG2, PRKAB2, PRKAG1 | WDR5 316/4885ALDH1A1 1088/4885NPC1 2085/4885 |
| US-20080009506-A1 | Imidazole Compound | KCNH2, KCNJ2, KCNH3 | WDR5 2632/4885ALDH1A1 2945/4885NPC1 3474/4885 |
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | WDR5 2228/4885ALDH1A1 3631/4885NPC1 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.